Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (HOPE II)
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study.
Sponsor: Botswana Harvard Health Partnership
Listed as NCT06436274, this PHASE4 trial focuses on Hiv and Human Papilloma Virus and remains ongoing. Sponsored by Botswana Harvard Health Partnership, it has been updated 6 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE4
-
Feb 2025 — Nov 2025 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE4
▶ Show 1 earlier version
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Botswana Harvard Health Partnership
- Fred Hutchinson Cancer Center
- Karolinska Institutet
- Massachusetts General Hospital
- Ministry of Health, Rwanda
- National Cancer Institute (NCI)
- University of Witwatersrand, South Africa
For direct contact, visit the study record on ClinicalTrials.gov .